These findings illustrate a novel circSCAP/SF3A3/p53 signaling axis involved in suppressing the malignance of NSCLC and provide a promising target for NSCLC prognosis prediction and treatment. This evidence concerns the gene SF3A3 and non-small cell lung carcinoma.